Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 10/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 8/20 | 0.44 |
| ▸ | PPARA | Q07869 | 8/20 | 0.44 |
| ▸ | PTGES | O14684 | 4/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.40 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.39 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4428605 | 1.00 | CA2 (0.47) | CA2MAPK1PPARGALOX5PPARA | |
| SCHEMBL6897326 | 1.00 | CA2 (0.47) | CA2MAPK1PPARGALOX5PPARA | |
| SCHEMBL27607352 | 0.94 | GPR84 (0.48) | CA2MAPK1PPARGALOX5PPARA | |
| SCHEMBL5612483 | 0.92 | GPR84 (0.52) | CA2GPR84FFAR1SLC1A2SLC1A1 | |
| SCHEMBL17292916 | 0.92 | GPR84 (0.52) | CA2GPR84FFAR1SLC1A2SLC1A1 | |
| SCHEMBL6889610 | 0.87 | CHRM1 (0.46) | CA2MAPK1PPARGALOX5PPARA | |
| SCHEMBL6889603 | 0.87 | CHRM1 (0.46) | CA2MAPK1PPARGALOX5PPARA | |
| SCHEMBL9985082 | 0.82 | CA2 (0.43) | CA2MAPK1PPARGALOX5PPARA | |
| SCHEMBL11506347 | 0.82 | CPB2 (0.50) | — | |
| SCHEMBL14776700 | 0.82 | CA2 (0.45) | CA2MAPK1PPARGALOX5PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2869820-A2 | PRODRUGS OF PEPTIDE EPOXY KETONE PROTEASE INHIBITORS | Onyx Therapeutics, Inc. (US) | 2015-05-13 | — | — | EP | disclosed |
| WO-2014011695-A2 | PRODRUGS OF PEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS, INC. (US) | 2014-01-16 | — | — | WO | disclosed |
| EP-1924275-B1 | THIO-CONTAINING INHIBITORS OF AMINOPEPTIDASE P, COMPOSITIONS THEREOF AND METHOD OF USE | SIMMONS WILLIAM H (US) | 2012-08-08 | — | — | EP | disclosed |
| EP-1924275-A4 | THIO-CONTAINING INHIBITORS OF AMINOPEPTIDASE P, COMPOSITIONS THEREOF AND METHOD OF USE | SIMMONS WILLIAM H (US) | 2009-07-29 | — | — | EP | disclosed |
| EP-1951316-A2 | MOLECULAR CONJUGATE | Ventana Medical Systems, Inc. (US) | 2008-08-06 | — | — | EP | disclosed |
| US-7390789-B2 | Thio-containing inhibitors of aminopeptidase P, and compositions thereof | SIMMONS WILLIAM H | 2008-06-24 | — | — | US | disclosed |
| EP-1924275-A2 | THIO-CONTAINING INHIBITORS OF AMINOPEPTIDASE P, COMPOSITIONS THEREOF AND METHOD OF USE | Simmons, William H. (US) | 2008-05-28 | — | — | EP | disclosed |
| WO-2007062177-A2 | MOLECULAR CONJUGATE | VENTANA MEDICAL SYSTEMS, INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007032887-A2 | THIO-CONTAINING INHIBITORS OF AMINOPEPTIDASE P, COMPOSITIONS THEREOF AND METHOD OF USE | SIMMONS WILLIAM H (US) | 2007-03-22 | — | — | WO | disclosed |
| US-20070060525-A1 | Thio-containing inhibitors of aminopeptidase P, compositions thereof and method of use | SIMMONS WILLIAM H | 2007-03-15 | — | — | US | disclosed |
| US-5654294-A | CARDIOVASCULAR DISORDERS | BRISTOL-MYERS SQUIBB (US) | 1997-08-05 | — | — | US | disclosed |
| EP-0783002-A2 | Dual action inhibitors | E.R. SQUIBB & SONS, INC. (US) | 1997-07-09 | — | — | EP | disclosed |
| US-5646276-A | ANGIOTENSIN CONVERTING ENZYME AND NEUTRAL ENDOPEPTIDASE INHIBITORS; CARDIOVASCULAR DISORDERS | BRISTOL-MYERS SQUIBB CO. (US) | 1997-07-08 | — | — | US | disclosed |
| US-5627278-A | MULTISTAGE REACTION FORMED BY AMIDATION, COUPLING AND REDUCTION | BRISTOL-MYERS SQUIBB CO. (US) | 1997-05-06 | — | — | US | disclosed |
| US-5616775-A | ESTERIFYING A N-PROTECTED METHIONINE; OXIDIZING; REACTING WITH AN ACID ANHYDRIDE THEN AN ALKALI METAL HYDROXIDE | BRISTOL-MYERS SQUIBB CO. (US) | 1997-04-01 | — | — | US | disclosed |
| US-5552397-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1996-09-03 | — | — | US | disclosed |
| US-5508272-A | SELECTIVE ACE INHIBITORS, HYPOTENSIVE AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-04-16 | — | — | US | disclosed |
| EP-0629627-A2 | Bicyclic carboxylic acids and their derivatives as nep and aca inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 1994-12-21 | — | — | EP | disclosed |
| EP-0599444-A1 | Dual action inhibitors | E.R. SQUIBB & SONS, INC. (US) | 1994-06-01 | — | — | EP | disclosed |
| CN-1084849-A | Dual action inhibitors | SQUIBB & SONS INC (US) | 1994-04-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060525-A1 | Thio-containing inhibitors of aminopeptidase P, compositions thereof and method of use | ACE, DNPEP, APP | CA2 921/4885MAPK1 3427/4885PPARG 3280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.